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Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease known by the presence 
of elevated blood glucose levels. Nowadays, it is perceived as a worldwide epidemic, 
with a very high socioeconomic impact on public health. Many are the complications 
caused by this chronic disorder, including a negative impact on the cardiovascular 
system, kidneys, eyes, muscle, blood vessels, and nervous system. Recently, there 
has been increasing evidence suggesting that T2DM also adversely affects the skeletal 
system, causing detrimental bone effects such as bone quality deterioration, loss of 
bone strength, increased fracture risk, and impaired bone healing. Nevertheless, the 
precise mechanisms by which T2DM causes detrimental effects on bone tissue are still 
elusive and remain poorly studied. The aim of this review was to synthesize current 
knowledge on the different factors influencing the impairment of bone fracture healing 
under T2DM conditions. Here, we discuss new approaches used in recent studies to 
unveil the mechanisms and fill the existing gaps in the scientific understanding of the 
relationship between T2DM, bone tissue, and bone fracture healing.
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iNTRODUCTiON
Type 2 diabetes mellitus (T2DM) is a very common comorbidity of obesity. It is characterized by 
hyperglycemia, resulting from insulin resistance and islet β-cell dysfunction (1). According to the 
World Health Organization (WHO), more than 422 million people are currently suffering from dia-
betes mellitus (DM), with T2DM accounting for 90% of these cases. WHO predicts DM to become the 
seventh leading cause of death in the world by 2030. Among its many complications, T2DM is known 
to cause a negative effect on the skeletal system (2–4). Currently, there are evidences suggesting that 
the process of bone healing after trauma (fracture) is compromised under T2DM conditions (5–7). 
Impaired vascularity and T2DM-enhanced inflammation impede the proper distribution of oxygen, 
nutrients, and osteoprogenitor cells to the repair site (8, 9). Cellular and molecular characteristics of 
the bone tissue are also altered under T2DM conditions in bone healing. For instance, it is suggested 
that not only the functionality of the osteoblasts (osteoprogenitors) may be compromised in the 
diabetic microenvironment but also that these cells are switching their differentiation fate toward 
the adipogenic lineage, increasing the amount of fat tissue in the fracture callus and thus hampering 
the fracture healing process (5, 10). Bone turnover has also been found to be altered in the presence 
of T2DM, having a negative impact in bone formation and/or bone resorption (11). Furthermore, 
the generation of advanced glycation end products (AGEs) due to the presence of hyperglycemia is 
FigURe 1 | Schematic representation of the selection procedure for the 
articles included.
TaBle 1 | Key terms used for the literature search performed in the PubMed 
database.
Key terms used in the search protocol Number of articles retrieved
Diabetes AND Fracture Healing 22
Type 2 Diabetes AND Fracture Healing 8
Diabetes AND Bone Regeneration 3
Diabetes AND Bone Healing 3
Diabetes AND Fracture Repair 4
Hyperglycemia AND Fracture Healing 4
Hyperglycemia AND Bone Regeneration 1
Diabetic Mice AND Fracture Healing 1
Diabetes AND Bone Formation 3
Hyperglycemia AND Bone Formation 2
Diabetes AND Non-union 2
Diabetes AND Callus Formation 6
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capable of altering the bone matrix and reducing the bone quality 
(12–14). Despite these reported evidences, the exact mechanisms 
of the pathology that T2DM causes on bone fracture healing 
remains poorly understood. In this review, we revised the differ-
ent T2DM-related factors that have been suggested to affect the 
bone fracture healing process and discussed recent findings to fill 
the current gaps in the scientific understanding of the impact of 
T2DM in bone repair.
MeTHODOlOgY
Focused Question
The following question was posed to define the content of this 
review article: what are the possible causes of impaired bone 
fracture healing in T2DM?
Search Protocol
Articles related to the topic of this review and potentially con-
tributing to answering the aforementioned proposed question 
were searched for, using the PubMed database of the US National 
Library of Medicine and National Institutes of Health. The key 
terms and their combinations input in the database for the search 
of potential articles are displayed in Table 1. The timeline for the 
selection of potentially relevant papers was set between January 
2007 and October 2017.
eligibility Criteria
The criterion, on which the selection of the articles to be included 
in the review was based, was the study of the fracture healing 
process under T2DM conditions. Different categories of studies 
were considered, including animal studies, clinical studies, and 
review papers. Some articles outlining the principal mechanisms 
of bone healing in normal conditions were also included. Articles 
solely focusing on type 1 diabetes mellitus (T1DM) were excluded 
from the final selection.
Search Process
The different steps of the literature selection procedure are 
shown in Figure  1. An initial search resulted in 59 retrieved 
papers. From this total, 30 articles were excluded after revision 
of the contents based on the eligibility criteria described above. 
Twenty-nine articles were considered relevant for inclusion. Of 
these 29 publications, 11 reports were categorized as animal 
studies (Table 2), 6 as clinical studies (Table 3), and 12 as review 
papers (Table 4).
BONe TiSSUe iN THe T2DM 
eNviRONMeNT
Cellular and Molecular Composition of the 
Diabetic Bone
A good way to understand the pathophysiological effects of T2DM 
on bone is to study the composition of bone tissue at cellular and 
molecular level. Older studies have reported a high level of non-
enzymatic cross-linking of the collagenous matrix, increasing the 
presence of AGEs that cause a lessened bone strength (40, 41). 
Collagen, in particular collagen type I, is a crucial protein in the 
maintenance of bone biomechanical strength due to its capability 
to generate intermolecular cross-links with adjacent collagen 
molecules. It has been shown that excessive non-enzymatic cross-
linking hampers osteoblastic activity and this possibly through 
the interaction with the cell surface receptor of AGEs (RAGE) (13, 
42), which decreases the synthesis of type I collagen, thus making 
collagen fibers brittle and accumulating excess microdamage. For 
this reason, AGEs are used as biomarkers for the assessment of 
increased risk of fractures (39).
Recently, a study from our group evaluated the levels of AGEs 
in bone from diet-induced obese (DIO) C57Bl/6 mice, under 
high-fat diet (HFD) treatment (43). By means of Raman spectros-
copy, ratios were calculated using the Raman-specific bands for 
the AGEs pentosidine (~1,495 cm−1) and carboxymethyl-lysine 
(CML; ~1,150  cm−1) and normalizing each to the CH2 band 
(1,450 cm−1), which represents the organic matrix of bone. It was 
observed that the cortical area of femora from DIO mice pre-
sented significant accumulation of AGEs when compared to age-
matched lean control mice, confirming the excessive generation of 
these species in bone under T2DM conditions (43). Furthermore, 
combined micro-computed tomography (microCT) analysis, 
three-point bending tests and finite element modeling revealed 
that DIO mice had reduced bone strength and structural stiffness, 
and increased material stiffness associated with the accumulation 
of AGEs in the bone tissue under T2DM conditions (43).
TaBle 2 | Animal studies on bone healing in type 2 diabetes mellitus (T2DM) published between January 2007 and March 2017 (in descending order).
Reference Study objective animal model 
and type of T2DM 
induction
Type of bone 
healing/
regeneration
Outcome
Wallner et al. (15) Compare different stages of bone 
regeneration between diabetic and 
non-diabetic mice and evaluate 
the efficacy of FGF-9 and vascular 
endothelial growth factor A (VEGF-A) 
in bone repair
C57Bl/6J mice (Lepr 
mutation db/db, 
spontaneous diabetes)
Unicortical bone 
defect (Tibia)
T2DM affects bone regeneration, through impairment 
of osteoclastogenesis and decreased biomarker levels 
in diabetic mice such as runt-related transcription 
factor 2, PCNA, and osteocalcin. Impairment of 
angiogenesis and osteogenesis could be reversed by 
local application of FGF-9 and VEGF-A, the latter to a 
lesser degree
Brown et al. (5) Study of the impact of T2DM on 
fracture healing
C57Bl/6J mice 
(diabetic-induced 
obese)
Tibia fracture 
model
Increased callus adiposity and likely a fate shift 
of mesenchymal stem cells (MSCs) toward the 
adipogenic lineage, could be involved in the observed 
weakened biomechanical properties and delayed 
fracture healing of diabetic bone
Chen and Wang (16) Observe change of FGF-2 and 
IGF-1 serum levels post-fracture 
and explore its mechanisms during 
healing
Sprague-Dawley rats 
[diet-induced obese 
(DIO) + streptozocin IP 
injection]
Tibia fracture 
model
Possible synergistic effects and decreased levels 
of FGF-2 and IGF-1 during fracture healing are 
accountable for impaired bone regeneration and 
delayed union in diabetic rats
Fontaine et al. (17) Evaluate the macrophage 
inflammatory protein 1 (MIP-1) and 
VEGF expression in a diabetic rat 
model of fracture healing
Zucker diabetic 
fatty (ZDF) rats 
(Lepr mutation fa/fa, 
spontaneous diabetes)
Femoral fracture 
model
Biomarkers expression highly differs between diabetic 
and non-diabetic conditions during fracture repair. The 
increased level of MIP-1 can be associated with the 
likelihood of delayed healing
Hamann et al. (18) Assess the effect of the parathyroid 
hormone (PTH) on skeletal and 
metabolic function in diabetic  
fracture healing
ZDF fatty rats (Lepr 
mutation fa/fa, 
spontaneous diabetes)
Femoral fracture 
model
Increased bone formation, increased bone strength, 
and improved defect regeneration suggest that PTH 
partially reverses the detrimental effects of T2DM on 
bone
Ro˝szer et al. (9) Assess the role of leptin in postnatal 
regenerative osteogenesis in diabetic 
mice
C57Bl/6J mice (Lepr 
mutation db/db, 
spontaneous diabetes)
Femoral fracture 
model
Deficiencies in leptin can be linked to compromised 
bone acquisition and regeneration capacity, through 
delayed periosteal mesenchymatic osteogenesis, 
premature apoptosis of cartilage callus, and impaired 
microvascularization
Hamann et al. (10) Assess the impact of diabetes on 
the structural and cellular properties 
of bone
ZDF fatty rats (Lepr 
mutation fa/fa, 
spontaneous diabetes)
Subcritical femoral 
defect model
Reduced ALP activity and mineralized matrix 
formation, suggesting osteoblast differentiation 
impairment and having an impact on bone mass and 
bone regeneration. Subcritical bone defect in diabetic 
rats demonstrated delayed healing in T2DM conditions
Jeyabalan et al. (19) Determine if the antidiabetic drug 
metformin shows adverse effects on 
bone mass and/or fracture healing
Wistar rats (n/a) Femoral fracture 
model
Bone mass and bone healing do not seem to be 
affected by metformin in rats. No differences in bone 
resorption, cortical and trabecular architecture, 
fracture callus volume and mineral content were found, 
compared to saline-treated controls
Liu et al. (20) Examine the potential side effects of 
rosiglitazone on bone formation in 
diabetic mice
Avy/a mice 
(spontaneous diabetes)
Distraction 
osteogenesis 
(Tibia)
Impact of diabetes on bone healing after distraction 
osteogenesis is unclear. Rosiglitazone decreased 
intramembranous endosteal bone formation and 
increased adipogenesis in the distraction gap of both 
diabetic and non-diabetic mice
Waddington et al. (21) Characterize biomarkers for oxidative 
stress and primary antioxidant 
enzymes during fracture healing in 
diabetic conditions
Goto-Kakizaki rats 
(spontaneous diabetes)
Mandibular 
implants
Delayed bone healing can be related to the absence 
of catalase enzyme activity, diminished by the affected 
oxidative environment due to hyperglycemia
Xu et al. (22) Determine the possible relationship 
between peroxisome proliferator-
activated receptor gamma (PPARγ) 
and core-binding factor α1 (Cbfα-1) in 
T2DM bone repair
Sprague-Dawley rats 
(DIO + streptozocin IP 
injection)
Distraction 
osteogenesis 
(Tibia)
Impaired fracture healing in T2DM rats may be caused 
by the increased expression of PPARγ mRNA and 
decreased levels of CBFα-1 mRNA in the bone marrow
3
Marin et al. Fracture Healing in Type 2 Diabetes
Frontiers in Endocrinology | www.frontiersin.org January 2018 | Volume 9 | Article 6
Evidence has also been pointed toward a detrimental effect 
of T2DM-induced hyperglycemia on osteoprogenitor cells. 
In a study from Hamann et  al. (10), osteoblast activity was 
found impaired in a model of Zucker diabetic fatty (ZDF) 
rats (10). Although there seemed to be a similar supply of 
osteoblastic precursors between the diabetic and non-diabetic 
TaBle 3 | Clinical studies on bone healing in type 2 diabetes mellitus published between January 2007 and March 2017 (in descending order).
Reference Main objective No. of patients Outcome
Hernigou et al. (23) Mitigate wound infection and promote 
non-union healing in diabetic patients by 
percutaneous injection of bone marrow 
mesenchymal stem cells (BM-MSCs)
172 Treatment with BM-MSCs increased fracture healing in 82% of the diabetic 
patients, compared to 62% of diabetic patients treated with standard bone iliac 
crest autograft
Wukich et al. (24) Compare the outcomes of retrograde 
intramedullary nailing for tibiotalocalcaneal 
arthrodesis (TTCA) in patients with and 
without diabetes
117 Despite an increased rate of superficial infections, retrograde intramedullary 
nailing proved to provide a high likelihood of successful limb salvage with TTCA 
in diabetic patients, similar to the outcomes of non-diabetic patients
Nozaka et al. (25) Evaluate the progression of ankle fracture 
healing in a diabetic patient after the use of 
an Ilizarov ring fixator
1 Patients suffering from diabetes experience difficulties during fracture healing 
with increased possibility of non-union. In cases of Charcot arthropathy in which 
the fragment diameter is very small, it is more suitable to use an Ilizarov ring 
fixator instead of internal fixation
Ricci et al. (26) Identify the risk factors for failure of lock plate 
fixation of distal femur fractures
326 It was determined that, along with open fracture, diabetes mellitus (DM) was an 
independent risk factor for reoperation to promote union and deep infection
Shibuya et al. (27) Determine the risk factors associated with 
non-union, delayed union and mal-union in 
diabetic patients after foot and ankle surgery
165 It was determined that surgery duration, hemoglobin A1c levels >7% and 
especially peripheral neuropathy are statistically significantly associated with 
bone healing complications
Kline et al. (28) Observe the rate of infection, rate of surgical 
complications, and the rate of non-union/
delayed union in DM vs non-diabetes during 
tibial pilon fracture repair
81 In diabetic patients, the rate of infection was 71% (43% deep infection), and the 
rate of non-union/delayed union was 43%, in comparison with 19% (9% deep 
infection) and a 16%, respectively, for non-diabetic patients. This demonstrates 
that the presence of diabetes elevates the risks of complications during the 
management of tibial pilon fractures
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rats (determined by colony-forming assays), T2DM conditions 
impaired osteoblast differentiation based on a 55% lower min-
eralized matrix formation after 21 days of cell differentiation 
(10). More recently, it was reported that the mineralization 
capacity and the alkaline phosphatase activity of bone mar-
row stromal cells (BMSCs) derived from rats under T2DM 
conditions was significantly decreased compared to controls. 
This impairment in osteogenic potential was explained by 
a significant reduction in reduced gene expression levels 
of β-catenin, cyclin D1, and c-myc, thus inhibiting the Wnt 
signaling pathway (44).
Biomarkers of Skeletal Dynamics in T2DM
According to the study from Reyes-García et al., the parathyroid 
hormone (PTH) can be linked to bone resorption in T2DM due to 
its positive association with the markers serum tartrate-resistant 
acid phosphatase-5b in T2DM patients, and serum terminal 
cross-linked telopeptide of type-I collagen (s-CTX) (45). The 
latter showed decreased levels in T2DM conditions according 
to several recent studies, along with the bone formation marker 
P1NP which was also found decreased (46, 47). Serum levels of 
TRAP and bone formation marker osteocalcin (OC) have been 
found diminished in T2DM patients, contrary to high serum 
levels of sclerostin (a potent inhibitor of bone formation) (48, 49), 
suggesting that individuals with T2DM present a reduced bone 
turnover. These data were supported by a recent study from our 
group, in which s-CTX and s-OC levels were found decreased in 
DIO mice, compared to age-matched lean controls (50).
It is important to highlight that there are conflicting results 
reported in existing literature for several of these biomarkers. 
Some studies report increased CTX levels, either unchanged 
or increased levels of OC (51, 52) and increased P1NP (53) in 
T2DM patients compared to healthy individuals. Differences 
in metabolic status, duration of the diabetic condition, and 
diabetic medication treatment being used by the time of the 
measurements might be responsible for these contradictions 
(11). Moreover, inconsistent results in the bone turnover process 
under T2DM conditions are also reported for rodent models 
in literature. T2DM models of rats have shown decrease bone 
formation with increased bone resorption (18, 54) in contrast 
to other studies showing lower levels of these parameters (55). 
Likewise, studies in T2DM mice models have showed different 
outcomes, with increased bone resorption (56) coupled with 
decreased or unchanged formation parameters (57), in contrast 
to decreased levels of bone resorption and formation (2, 50) and 
even reports showing increased bone turnover with higher levels 
of both resorption and formation in the T2DM group (3). These 
contradictory results may also be explained by the duration of 
the HFD treatment and the disease, the own response of each 
species’ strains to the T2DM effects, or by the different levels of 
expression of skeletal growth modulators such as PTH and IGF-1, 
which have been associated with the bone resorption and/or bone 
formation processes (58, 59).
vascularization of Bone under T2DM 
Conditions
Blood supply is critical for the development and proper function-
ality of bone tissue, providing oxygen, nutrients, and minerals 
essential in bone regeneration (60). Many studies have addressed 
and demonstrated the key role of the vasculature and angiogenesis 
in fracture repair, evaluating the contribution of elements such as 
endothelial progenitor cells (EPCs), ischemia, and proangiogenic 
factors such as vascular endothelial growth factor (VEGF) and 
HIF1α (61–63).
TaBle 4 | Review articles on bone healing in type 2 diabetes mellitus (T2DM) 
published between January 2007 and March 2017 (in descending order).
Reference article’s focus
Bahney et al. (29) Review recent insights into the role of vascularization 
during the fracture healing process and highlight the 
need for an update in the endochondral repair model to 
promote adequate bone healing
Hayes and Coleman 
(30)
Revision of the literature supporting the application of 
MSCs in fracture repair in diabetic conditions and the 
possible causes promoting the dysfunction of the bone 
fracture healing process
Jiao et al. (31) Study of different aspects that have been shown 
to impact bone and the skeletal repair process 
in T2DM, such as inflammation, reactive oxygen 
species formation, advanced glycation end products, 
hyperglycemia, especially in osteoblast differentiation 
and cellular bone turnover
Dede et al. (32) Study the causes involved in the promotion of fracture 
risk in patients with T2DM, and discussion of the 
influence of reported research outcomes such as higher 
BMD, AGEs accumulation, and suppression of bone 
turnover under diabetic conditions on fracture risk
Fadini et al. (33) Revision of the physiological and molecular bone 
marrow abnormalities associated with diabetes and 
also representing a potential root for the development of 
multiorgan failure characteristic of advanced diabetes
Razzouk and Sarkis 
(34)
Description of the impact of epigenetics on diabetes 
mellitus and smoking, and their significance in bone 
repair
Sathyendra and 
Dorowich (35)
Discussion of the factors influencing bone healing, such 
as diabetes, and the biology involved in the regeneration 
of new bone after fracture
Borrelli et al. (36) Revision of the negative influence that certain clinical 
conditions, such as chronic inflammation, diabetes, 
aging, etc., exert on bone repair after fracture
Claes et al. (37) Study the main factors promoting fracture healing 
impairment, with a particular emphasis on the role of 
inflammation
Simpson et al. (38) Investigate the effect exerted by the main classes of 
diabetic drugs on the skeletal system, with special focus 
on fracture healing
Roszer (8) Summarize the most recent reports supporting the 
idea that inflammatory signaling increases chondrocyte 
and osteoblast death and prolongs osteoclast survival, 
resulting in impaired bone regeneration in diabetic 
conditions
Retzepi and Donos 
(39)
Discuss the clinical evidence supporting a higher rate of 
complications during fracture healing in diabetic patients 
and provide a synthesis of the possible molecular 
mechanisms that are part of the diabetic bone healing 
pathophysiology
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It is known that T2DM is associated with several vascular 
complications including diabetic neuropathy, nephropathy, 
retinopathy, peripheral vascular disease, ischemic heart disease, 
among others (64–68). Arterial medial calcification is caused 
by the biomineralization of vascular cells, impairing the arte-
rial vessel system and thus the functionality of the vasculature 
(67). Several findings have tried to explain this phenomenon, 
including the identification of upregulated bone alkaline phos-
phatase, a known modulator of mineralization (69), helped by 
elastin degradation in blood vessels undergoing arterial medial 
calcification (70). Another possible mechanism for arterial 
stiffening is the role of the transcription factor Msx2 in vascular 
mineralization. A model of Msx1 and Msx2 gene deletion in 
obese HFD-fed LDLR(−/−) mice showed that decreased levels 
of these transcription factors (34 and 95%, respectively) resulted 
in reduced expression of Wnt genes and aortic osteogenic 
progenitors, such as Shh and Sca1, thus limiting the osteogenic 
differentiation and mineralization potential of cells involved in 
vascular calcification (71). Moreover, studies have shown that 
AGEs and RAGE seem to play a role in vascular calcification, 
which implicates further potential complications for T2DM 
patients. A recent study from Koike et al. assessed the effects of 
AGEs on the rat vascular smooth muscle cell (VSMC) line A7r5 
in  vitro. Cells incubated with AGEs in calcification medium 
exhibited increased calcium deposition compared to bovine 
serum albumin cells (control). Visualization and quantification 
of significantly increased VMSCs apoptosis after treatment with 
AGEs was possible by means of TUNEL and Hoechst stainings, 
showing an AGE-induced apoptosis of 83% compared to 1% in 
controls (72). Moreover, mRNA expression of the NAD(P)H 
components Nox1, Nox4, and p22phos was significantly upregu-
lated in AGEs treated VSMCs, and when these components were 
silenced after siRNA transfection, AGE-induced apoptosis was 
markedly reduced (42–47%). These data suggest that the activa-
tion of NAD(P)H oxidase regulates the AGE-induced apoptosis 
of VSMCs (72). In addition to this, another study explored the 
mechanism of AGE-induced diabetic calcification using also the 
same cell line A7r5 (73). In this case, the VSMCs also showed 
increased levels of AGE-induced arterial calcification, and 
the serum level of the AGEs species CML was positively cor-
related with calcium content in the arterial walls. Furthermore, 
the CML/RAGE signal intensity seemed to increase with the 
diabetes-induced vascular calcification progression, and when 
the calcification pathway was blocked by using anti-RAGE 
antibodies, the calcium deposition and ALP activity were 
significantly reduced by approximately 50% (73). This confirms 
results from previous studies suggesting that AGEs accumula-
tion is detrimental for vascularization and thus for bone tissue 
health in T2DM conditions.
In addition to the T2DM-induced vascular calcification, the 
vascular progenitor cells seem to be affected by the metabolic 
disease. EPCs are known for their expression of endothelial 
markers (VEGF, CD34) and enhancement of angiogenesis after 
differentiating into mature endothelial cells (74), thus aiding in 
wound healing and tissue regeneration with their proangiogenic 
capacities. In a study from Lombardo et  al., analysis of differ-
ent subpopulations of EPCs and circulating endothelial cells in 
peripheral blood was carried out on patients suffering from T2DM 
and healthy controls. It was found that T2DM individuals showed 
an increased number of highly immature EPCs (pre-EPCs) 
expressing early hematopoietic markers CD117 and CD133 (74). 
Levels of EPCs (coexpressing CD34/VEGF/CD133) and highly 
differentiated EPCs, or “late-EPCs” (coexpressing VE-cadhering 
and CD31) were also assessed. Results showed that there was no 
FigURe 2 | (a) 3D representation generated after micro-computed tomography (microCT) scanning of the subcritical femoral defect model in control vs type 2 
diabetes mellitus (T2DM) rats, 12 weeks post-surgery. (B) microCT-based quantification of the bone defect filling in control and T2DM femora, 12 weeks post-
surgery. n = 7–10. ap < 0.01. Figure taken and adapted from Ref. (10).
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significant difference between EPCs level of T2DM and control 
groups. On the other hand, a highly significant decrease of late-
EPCs level was found in T2DM individuals (74).
All this sets a precedent of the state in which bone tissue under 
T2DM conditions may be before a fracture event occurs.
BONe FRaCTURe HealiNg iN NORMal 
CONDiTiONS
When bone tissue gets damaged, the fracture healing process is 
successfully completed when the proper biological and mechani-
cal conditions for tissue repair exist and the surrounding micro-
environment, i.e., the host bed, is not compromised. This process 
undergoes a sequence of biological events that have been clearly 
described and divided by Claes et  al. (37) into three phases: 
inflammation, repair, and remodeling. The description of these 
phases has been based on the well-studied rat fracture healing 
model (75). The process is similar for humans and for other larger 
animal models, taking place over longer periods of time.
In the inflammatory phase, vasodilatation and exudation of 
plasma and leukocytes occur at the site of the lesion after the 
rupture of blood vessels and damage of the bone and surround-
ing tissues. Then, a fracture hematoma is formed, characterized 
by the presence of different inflammation-related cells, such as 
macrophages, leukocytes, and cytokines. Among the cytokines 
are interleukin 1 (IL-1) and 6 (IL-6), TNF, members of the 
transforming growth factor beta (TGF-β) superfamily like bone 
morphogenic protein 2 (BMP-2) and 6 (BMP-6), and angiogenic 
factors such as VEGF. Stimulation of the angiogenesis process 
occurs, and newly formed blood vessels provide access to osteo-
progenitor cells that will contribute to fracture repair. Next, the 
hematoma gets progressively replaced by a granulation tissue 
containing collagen, produced by fibroblasts, cells, and new 
capillaries (37).
The second phase is the repair phase. The anabolic mechanism 
for the periosteal callus formation is endochondral ossification, 
with the primary development of a soft cartilaginous callus 
succeeded by its transformation into a hard bony callus, usually 
temporally overlapping with the inflammatory phase (76). After 
10–14  days of chondrocyte proliferation in fracture healing 
experiment involving rats, cell hypertrophy, calcium release, 
and subsequent apoptosis have been observed (77). Once the 
cartilaginous callus segments successfully bridge the fracture, 
blood vessels are allowed to occupy the calcified cartilage area 
and promote hypervascularization due to reduced interfragmen-
tary movement and tissue strain during loading of the fracture. 
Hypervascularization in turn stimulates the recruitment of 
monocytes and mesenchymal stem cells (MSCs), which will 
differentiate into osteoclasts and osteoblasts, respectively; the 
former resorbing the calcified cartilage and the latter generating 
new bone tissue into the resorbed lacunae, ultimately leading to 
the formation of woven bone with a trabecular structure (37).
Finally, after the fracture gap has been filled with new woven 
bone, osteoclastic activity takes place at the outer surface to start 
the resorption of the periosteal callus and therefore the onset of 
the remodeling phase. The previously formed woven bone tissue 
gets transformed into lamellar bone through osteon forma-
tion, and the remodeling and resorption of the periosteal and 
medullary calluses conclude with the successful reshaping of a 
diaphyseal bone, a process that can take between 5 and 8 weeks 
in rats and years in humans. Some characteristics of this phase 
are the diminishing of the vascularization process to pre-fracture 
levels and the reduction of inflammatory cytokine levels, with the 
exception of IL-1, TNF, and BMP-2, which can still be found to 
be highly expressed (37).
BONe FRaCTURe HealiNg UNDeR  
T2DM CONDiTiONS
The result of the normal fracture healing process is the obtain-
ment of a fully loadable and reconstructed bone. However, in 
the presence of hyperglycemia, bone tissue experiences altera-
tions in quality, composition, and biomechanical properties 
and these can lead to fracture healing impairment or even 
non-union (21, 37, 78).
Imaging techniques such as micro- and nanoCT stand as a 
powerful tool to accurately assess the progression of bone repair 
(Figure  2). In 2014, a study from Brown et  al. using C57BL/6 
T2DM-induced mice demonstrated delayed fracture heal-
ing, increased callus adiposity, and hampered biomechanical 
FigURe 3 | Assessment of adipocyte presence in the fracture callus of control and type 2 diabetes mellitus (T2DM) mice tibiae through immunological staining for 
peripilin. Right panels show a magnified area of the sections, where stained adipocytes (red arrows) can be appreciated more clearly. Timepoint post-fracture 
surgery: 21 days. Black scale bar in left panel = 1 mm. Black scale bar in right panel = 100 µm. Figure taken and adapted from Ref. (5).
7
Marin et al. Fracture Healing in Type 2 Diabetes
Frontiers in Endocrinology | www.frontiersin.org January 2018 | Volume 9 | Article 6
properties in T2DM conditions. Using microCT scanning, 
the authors were able to observe that there was a trend toward 
decreased callus vascular volume and a significant decrease in 
fracture callus bone volume at day 21 after fracture in HFD-fed 
mice compared to control mice. Furthermore, delay in reaching 
peak bone volume and a significant decrease in woven bone area 
was found at day 28 post-fracture in HFD-fed mice. The authors 
also discussed the presence of increased adiposity found in frac-
ture calluses of HFD-fed mice only (Figure 3). It is proposed that 
the balance of MSCs differentiation toward osteoblast and adipo-
cyte lineage is altered to favor the latter. It is further discussed that 
the upregulated levels of PPARγ found in the fracture calluses of 
HFD-fed mice are indeed most likely promoting the MSCs fate 
switch. Finally, it was determined that during the entire fracture 
healing process the osteoclast phenotype remained within nor-
mal parameters (5). This was also confirmed in a study using ZDF 
rats where osteoclast function did not show differences between 
diabetic and control animals (10). The observed abnormality of 
increased PPARγ expression and elevated marrow adiposity in 
the femoral diaphyseal area has been confirmed by other studies 
(3, 22), using the DIO C57BL/6J mice model under HFD treat-
ment and comparing to low-fat diet-fed mice (3), confirming the 
T2DM fracture healing impairment cocaused by the event of fate 
switch from osteoblasts to adipocytes.
The decreased capability of MSCs committing to osteo-
blastic differentiation is further evidenced by the inhibition of 
expression of transcription factors, crucial for the development 
of the osteoblastic phenotype such as Dlx5 and runt-related 
transcription factor 2 (Runx-2), during intramembranous bone 
healing in a marrow ablation model (79). Moreover, reduced 
immunohistochemical indices (up to 50%) of cell proliferation 
rate in the diabetic callus further support the decreased number 
of osteoblasts as part of the mechanism for impaired bone healing 
(80). In addition, protein expression levels of several growth 
factors closely related to osseous healing such as PDGF, IGF-1, 
VEFG, and TGF-β1 have been reported to decrease in diabetic 
rodents models (80, 81). Particularly for VEGF, several studies 
report alterations in its expression levels during the fracture heal-
ing process under T2DM. Rőszer et al. (9) studied the femoral 
fracture healing model in leptin receptor-deficient (db/db) 
T2DM mice. After 7 and 14 days post-surgery, the authors found 
a low VEGF expression in the plasma and callus tissue of the db/
db mice, compared to lean control mice. In addition, deficient 
microvascular invasion and elevated chondrocyte apoptosis in 
the fracture callus of the db/db mice were shown, suggesting a 
compromised cartilage-to-bone transition and explaining the 
delayed bone healing in these mice (9). Impaired angiogenesis 
was also observed in another study using the db/db T2DM mouse 
model to assess the tibial fracture healing process (Figure 4). An 
additional study involving femoral fracture models using ZDF 
rats (17) also demonstrated a significant decrease in the serum 
levels of VEGF at different timepoints during the early stages of 
the fracture healing process (2 weeks). In addition, the expres-
sion levels of macrophage inflammatory protein 1α, known to be 
highly involved in osteoclastogenesis, were found increased in the 
serum of the rats with T2DM. This may be potentially extending 
osteoclast activity during bone repair and compromising the 
healing process (17).
Nevertheless, the effect that T2DM causes to osteoclasts 
remains controversial in literature. An in vitro study evaluating 
the murine monocytic cell line RAW264.7 reported that high 
concentrations of D(+)Glucose (25 mM) inhibited TRAP activity 
and osteoclast differentiation induced by RANKL (a key factor in 
osteoclastogenesis) (82). In contrast, other studies involving cir-
culating osteoprogenitor precursors (human) and BMSCs (mice) 
have reported an increase in osteoclast and osteoclast precursor 
FigURe 4 | (a) Fluorescence immunohistochemistry staining for PECAM-1, 
to detect the presence of blood vessels and endothelial cells in control vs 
type 2 diabetes mellitus (T2DM) mice tibiae, 3 days post-surgery. (B) 
Magnification of the areas in (a) represented by white squares. White arrows 
signal blood vessels and endothelial cells, stained in red. White scale bar in 
(a): 200 µm. White scale bar in (B): 45 µm. Figure taken and adapted from 
Ref. (15).
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numbers by TRAP staining, and increased expression of the 
osteoclast-specific biomarker cathepsin K (46, 83). Nonetheless, 
when the in  vivo bone fracture healing model is assessed the 
data suggest no changes in the osteoclast compartment. Several 
fracture healing studies in mice and rats agree with the fact that 
osteoclast number and functionality remain unchanged during 
bone repair under T2DM conditions, in terms of TRAP-staining 
positive cells and TRAP mRNA expression levels (5, 10). It is 
possible that the stress caused by the fracture event in the in vivo 
T2DM microenvironment alters the mechanisms governing 
osteoclast functionality.
Biomarkers of bone formation and resorption during the 
fracture healing process have also been evaluated. A study from 
Chen and Wang (16) showed that serum and fracture callus 
levels of FGF-2 and IGF-1 were significantly decreased in a tibial 
fracture healing model of diabetic rats. It was also noted that rats 
with DM presented less density and area of newly formed bone at 
the fractured ends of the tibiae (16). The study by Wallner et al. 
(15) characterized the bone regeneration process at different 
timepoints by means of a unicortical bone defect model applied 
to T2DM and control mice. Immunohistochemical stainings for 
OC and RUNX-2 were performed at days 3, 5, and 7 post-surgery, 
revealing a significant decrease in the levels of both biomarkers in 
T2DM mice, specifically at days 3 and 7 post-surgery for RUNX-2 
and OC, respectively. It can be speculated that the decreased 
OC level in T2DM mice is caused by the decreased RUNX-2 
levels at the early stage of the fracture healing process, since 
RUNX-2 is known for regulating OC expression (15). Moreover, 
Hamann and coworkers published two studies (2011 and 2014) 
where levels of OC were measured in a critical-sized (10) and 
in a subcritical-sized (18) bone defect model in T2DM rats. In 
both studies, OC levels were diminished, by 40% (10) and 52% 
(18), respectively. Serum levels of the biomarker CTX were also 
measured, and in both studies these were found to be increased 
by threefold in T2DM rats, compared to healthy controls (10, 
18). In addition, TRAP levels were increased by 70% in diabetic 
rats (18). The results from these studies confirm diminished 
bone formation and increased bone resorption in T2DM bone 
fracture healing. Taken together, these findings on biomarker 
tracking during skeletal tissue repair support the idea that bone 
healing and regeneration is impaired by T2DM, particularly via 
the alteration of the bone turnover process.
The inflammatory phase of the fracture healing process is 
crucial for providing oxygen, nutrients, and the osteoprogenitor 
cells necessary for the bone repair (37). It is known that T2DM 
favors an increased inflammatory state, which alters several fac-
tors involved in the mechanisms of bone healing and promotes 
the activation of inflammatory mediators, such as reactive oxy-
gen species (ROS) and AGEs (8). One key mediator present in 
the early inflammatory response after bone fracture which starts 
the bone repair process is TNF-α. This inflammation-related 
factor and the members of the TNF-α receptor family have been 
identified to play a key role in the initiation of apoptosis (8). 
Bone fracture healing models of T1DM CD-1 mice have been 
used for the assessment of the effects of TNF-α on the bone 
repair process. It was reported that TNF-α triggers the expres-
sion and activity of proapoptotic factors such as caspase-3, -8, 
and -9, inducing chondrocyte apoptosis, resulting in reduced 
callus and cartilage area (84). Furthermore, TNF-α contributes 
to the endothelial cell proliferation impairment, reduced tube 
formation, and suppressed VEGF expression in fractured tibiae 
and femora of mice, compromising the angiogenesis of the heal-
ing process (85). The effect of TNF-α on bone was mediated 
by FOXO1, a transcription factor involved in the expression of 
the proapoptotic factors p21 and caspase-3 (85). Even though 
these biological events have not been explored in bone fracture 
healing of a T2DM animal model, the findings in the fractured 
bone of T1DM mice set a precedent for what may be happening 
in the former. This idea is supported by a study from Halade 
et al. (86), which showed increased gene expression of TNF-α in 
femora from obese, hyperglycemic, and insulin-resistant mice, 
fed with a corn oil-enriched diet (86).
CliNiCal COMPliCaTiONS OF  
DiaBeTeS iN BONe SURgeRY
Diabetes mellitus has been classified as a risk factor for failure in 
operative procedures for bone fractures due to post-surgery com-
plications (26). Patients suffering from DM that need to undergo 
fracture surgery have shown an increased rate of complications 
after the procedure has been carried out (25, 87). In 2009, a study 
including 81 patients (14 fractures in 13 individuals with DM, 
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69 fractures in 68 non-DM individuals) who received primary 
treatment for a tibial pilon fracture, determined the rate of infec-
tion, the rate of delayed union, non-union, and rate of surgical 
wound complication after the procedure (28). Though the rate 
of surgical wound complication presented no differences (7% 
for both groups of individuals), the rate of infection in patients 
suffering from DM was as high as 71% (43% for deep infections), 
compared to 19% for patients without DM (9% deep infection). 
Furthermore, the rate of delayed union/non-union was reported 
to be 43% for DM patients, against a 16% for controls (28). 
A study from Wukich et  al. (24) also showed a higher rate of 
superficial infection in patients with DM, although it was shown 
at the same time that the overall incidence of complications 
between patients with and without DM was not significantly 
different (24). Another study included 165 patients suffering 
from DM that underwent arthrodesis, osteotomy, or fracture 
reduction. The objective was to determine which diabetes-related 
comorbidities, including tobacco use, peripheral vascular disease, 
peripheral neuropathy, among others, were positively associated 
with fracture delayed union, non-union, and mal-union after 
foot and/or ankle surgery (27). After bivariate analyses and 
covariates adjustments, results showed that the surgery duration, 
HbA1c levels >7% and particularly peripheral neuropathy were 
predictors for bone healing impairment in individuals with DM 
after surgery (27). Specifically for ankle fracture, it is known that 
around 30% of patients with DM do not regain complete func-
tionality after treatment, compared to only 10% of incomplete 
functional recovery in cases without DM (88, 89). Amputation 
is another concern among patients with DM after ankle fracture. 
A fourfold to fivefold increased rate of amputation after fracture 
treatment has been reported in patients with DM in comparison 
to controls (90–92). In the case of open ankle fractures, this rate 
increases even more, up to an alarming 42% (93).
Regarding hip fractures, they are among the most common 
orthopedic fractures, having a yearly incidence as high as 1% in 
the United States (94, 95), and they are likely to increase also in 
the UK in the next 15 years (96). T2DM is known to increase this 
incidence rate by 1.4- to 1.8-fold (97, 98) due to mechanisms still 
not fully understood (99, 100). It has been reported that T2DM 
decreases the strength of the femoral neck of rats by 64% when 
compared to healthy controls (101). As seen in patients with 
several other orthopedic fractures, T2DM is likely associated with 
complications after treatment of hip fracture, such as surgical site 
infection, pressure ulcers, cardiac post-operative complication, 
and increased rate of mortality (102–104).
eFFeCTS OF aNTiDiaBeTiC MeDiCaTiON 
ON THe HOMeOSTaSiS aND RePaiR OF 
THe DiaBeTiC BONe
One important factor to take into account when studying bone 
fracture healing in patients suffering from T2DM is their history 
of the use of antidiabetic medication. Some blood glucose-low-
ering treatments have been associated with alterations in skeletal 
properties (53, 105), which can be either beneficial or detrimental 
for the process of fracture healing.
Thiazolidinediones (TZDs), including pioglitazone, rosigli-
tazone, and troglitazone, are a family of synthetic PPARγ agonist 
drugs. TZDs are widely used as treatment for T2DM patients 
because of their effective improvement of insulin sensitivity, but 
have also been proven to act adversely against skeletal homeo-
stasis (106, 107). The first clinical evidence of TZDs relation to 
bone fracture risk was reported in the “A Diabetes Outcome 
Progression Trial” studies (108, 109). The authors found that 
the increased risk of fracture manifested after 12  months of 
treatment, and the cumulative risk of fracture was 15.1% for 
rosiglitazone female T2DM patients, compared to 7.3 and 7.7% 
for metformin and glyburide females T2DM patients, respec-
tively (109). Due to their nature as PPARγ agonists, it has been 
proposed that TZDs favor a preferential differentiation of bone 
marrow MSCs into the adipogenic lineage, decreasing commit-
ment toward osteoblast differentiation, thus disrupting cellular 
homeostasis (110). In vivo experiments using primary human 
BMSCs revealed that TZDs reduced the number of osteoblast 
positive colonies and the RNA expression of osteogenesis mark-
ers Runx2 and OC, but the adipogenic differentiation was favored, 
after observing increased adipocytes colony-forming units and 
PPARγ RNA expression (111). Furthermore, a study from van 
Lierop et  al. (53) assessed the effect of metformin on serum 
sclerostin and other bone biomarkers. Metformin is a popular 
antidiabetic oral drug used among T2DM patients, which has 
been associated with decreased fracture risk (100) and increased 
osteoblast differentiation by transactivation of RUNX2 (112). 
Compared to healthy, untreated control subjects, the authors 
found that male T2DM patients under TZDs treatment expe-
rienced an increase of 11 and 16.8% in s-sclerostin and s-CTX 
levels, respectively, contrary to the metformin-treated group, 
which did not show any significant changes in s-sclerostin but 
had a 19% decrease in s-CTX (53). Another study followed up 
for 15 years the treatment with metformin in a cohort at very 
high risk of developing diabetes. Results showed that the diabe-
tes incidence was reduced 18% in metformin-treated subjects 
compared to the placebo group, and the cumulative incidences 
of diabetes were 56% for subjects receiving metformin and 62% 
for placebo subjects (113).
An antidiabetic medication that has also been reported to 
produce osteogenic effects is the glucagon-like peptide 1 recep-
tor agonist (GLP-1RA). Studies involving ovariectomized rodent 
models have shown that after GLP-1RA treatment, trabecular 
bone mass and connectivity, s-OC and s-alkaline phosphatase 
levels, and osteoclast numbers are significantly increased, but 
osteoclast activity and s-CTX levels are decreased compared to 
untreated controls (114, 115). Furthermore, in vitro experiments 
showed that sclerostin expression was decreased in osteocyte-like 
MLO-Y4 cells under hyperglycemic conditions and GLP-1RA 
treatment (116). The authors confirmed the osteogenic effect 
in  vivo, reporting decreased s-sclerostin levels, and increased 
BMD and s-OC levels in T2DM OLEFT rats treated with the 
antidiabetic medication (116).
The sodium-glucose cotransporter 2 (SGLT-2) inhibitors are 
another kind of drugs prescribed to T2DM patients. They con-
trol hyperglycemia by increasing the urinary glucose excretion, 
reduce body weight, and reduce body fat mass (117, 118). A recent 
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study showed that, over the course of 104 weeks treatment, a 7.7% 
of T2DM patients under dapagliflozin (a commercially available 
SGLT-2 inhibitor) presented bone fractures, though the exact 
cause of this increase in fracture risk is rather uncertain (119). 
Other studies have reported increased levels of CTX and OC 
biomarkers (120), and an increase of serum phosphate levels (121, 
122), in T2DM patients under treatment with SGLT-2 inhibitors. 
The latter findings may imply a potential upregulation of the PTH 
hormone (secondary hyperparathyroidism), triggering bone 
resorption and thus favoring fracture risk (105, 123).
The effects of additional antidiabetic medications, such as 
sulfonylureas and DPP-4 inhibitors, have been covered previously 
in literature, and together with the ones addressed in this article, 
are very well described in a review by Palermo et al. (124).
A topic that remains highly underexplored is the impact of 
antidiabetic drugs on bone fracture repair. A study from Liu 
et  al. using a mouse model of T2DM (Avy/a mice strain) and 
distraction osteogenesis evaluated the effects of rosiglitazone on 
the bone repair process (20). After 2 weeks of osteotomy surgery, 
microCT analysis revealed that the distraction gap area occupied 
by new bone was reduced from 66 to 43% when untreated and 
rosiglitazone-treated Avy mice were compared, respectively. In 
addition, histological and immunohistological assays determined 
that in the fracture site of rosiglitazone-treated mice, marrow fat 
presence was significantly increased, osteoprogenitors highly 
expressed adipocyte protein 2, and cell proliferation was compro-
mised (20). Consequently, it is speculated that the use of TZDs is 
disadvantageous for the fracture repair process in T2DM patients. 
On the other hand, metformin was evaluated in another study 
using 3-month-old Wistar rats undergoing femoral osteotomy 
(19). The authors found no differences in cortical and trabecular 
thickness, trabecular bone volume and number, and periosteal 
and endosteal perimeter between the metformin-treated and 
untreated groups 4 weeks after fracture surgery. Taking all this 
into account, as more evidence is unveiled about the detrimental 
effects of many antidiabetic drugs on the skeletal system, the 
future direction of the line of research should be focused more 
on further proving the beneficial (or lack of) effects of metformin 
and other antidiabetic medications such as GLP-1RAs on bone 
tissue, so it can be taken fully into consideration when choos-
ing the current safest alternative for T2DM treatment in bone 
fracture patients.
POSSiBle THeRaPeUTiC STRaTegieS 
FOR COMPROMiSeD BONe RePaiR 
UNDeR T2DM CONDiTiONS
In the field of bone tissue engineering, MSCs represent a promis-
ing cell-based alternative against the challenges of treating bone 
FigURe 5 | Schematic representation of both the bone tissue state and the different factors involved in the impairment of the fracture healing process, under type 2 
diabetes conditions. T2DM, type 2 diabetes mellitus; AGEs, advanced glycation end products; TZDs, thiazolidinediones; Scl, sclerostin; CTX, terminal cross-linked 
telopeptide of type-I collagen; OC, osteocalcin; TNF-α, tumoral necrosis factor alpha.
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defects, due to their self-renewal characteristics, the possibility 
to isolate them from many types of tissue and their ability to 
differentiate into multiple cell lineages (125). For instance, it was 
reported that treatment with autologous bone marrow MSCs was 
able to favor healing of non-union ankle fractures in patients 
suffering from DM (23). A great source of this type of cells is 
the periosteum, a structure covering the external surface of bone 
which is known to be crucial in the recruitment of osteopro-
genitor cells during the events of bone regeneration and fracture 
repair (126–128).
Periosteum-derived cells (PDCs) have been used previously 
in tissue engineering approaches to study bone formation. By 
seeding human PDCs in calcium-phosphate scaffolds, it was 
possible to confirm the bone forming capacity of these con-
structs in an in vivo ectopic implantation model of NMRInu/nu 
mice (129). With this in mind, the potential regenerative power 
of PDCs look promising to be used in the form of tissue engi-
neering constructs implanted in the diabetic microenviron-
ment, to aid and enhance the bone healing process impaired 
by T2DM.
A recent study from Tevlin et al. (130) investigated the rescue 
of skeletal stem cells derived from the diabetic microenvironment 
to aid the bone fracture healing process. The authors discovered 
that, during femoral repair, the fracture-induced expansion of 
these diabetic stem cells was compromised by elevated levels of 
TNF-α, inhibiting in turn the expression of Indian hedgehog, and 
altering the expression of apoptosis-related and proliferation-
related genes (130). Moreover, after local delivery of an Indian 
hedgehog-coated hydrogel into the fracture site of T2DM mice, 
mechanical strength tests showed improved bone strength, 
elevated proliferation, reduced apoptotic activity, and enhanced 
osteogenesis of the diabetic skeletal stem cells. These data dem-
onstrated that the correction of progenitor cells derived from a 
compromised niche such as the diabetic microenvironment can 
be a potential therapeutic strategy for the rescue of the bone 
fracture healing process (130).
As previously discussed, impairment of vascularization and 
angiogenesis associated with T2DM greatly affect the bone heal-
ing process. Therefore, it is of utmost importance to find new 
approaches that can contribute to adequate vascular functional-
ity in the aid of bone repair. Two studies evaluated the rescue of 
the functionality of impaired bone marrow-derived angiogenic 
cells (BMACs) from T2DM animals. Using the microRNA miR-
27b mimic/inhibitor, Wang et al. (131) observed that, compared 
to controls, miR-27b mimic increased BMACs proliferation, 
adhesion, tube formation, delayed apoptosis, and suppressed 
expression of the anti-angiogenic protein semaphoring 6A and 
the pro-oxidant protein p66, which elevates mitochondrial ROS 
levels, thus increasing the angiogenic potential of the BMACs 
(131). Another study assessed the rescue of the angiogenic 
function of BMACs derived from T2DM animals via overex-
pression of adenoviral vector-mediated dominant negative 
Rac1, hampering functionality of endogenous Rac1, subunit 
of NADPH oxidase, which was found to have an increased 
activity in these cells (132). Results showed that tube number, 
tube length, adhesion, and migration ability were all seemed 
increased in the BMACs after treatment, compared to controls 
(132). Overall, recent relevant studies have been done on the 
rescue of the vascularization in the diabetic microenvironment, 
especially in the field of endothelial progenitors and proangio-
genic cells. Nonetheless, research efforts should focus more on 
the impaired vascular system’s rescue during fracture healing 
under T2DM, as it remains as a much-underexplored topic. 
Much further experimentation is still needed to elucidate the 
detrimental effects of T2DM on vascularization during bone 
repair, for researchers to achieve an enhanced and successful 
fracture healing process under compromised conditions such 
as T2DM.
CONClUSiON
The process of bone healing after fracture is highly compromised 
by different factors altered by T2DM (Figure 5). The detrimental 
effect of T2DM on the regenerative ability of bone seems to 
be acting at cellular, molecular, and biomechanical levels. Fate 
switch of MSCs favoring the adipogenic lineage causes a signifi-
cant decrease in woven bone area and creates a negative impact 
on bone formation and cellular composition. On the other hand, 
an exacerbated presence of AGEs allows the formation of exces-
sive non-enzymatic cross-linking, hampering type I collagen 
synthesis and promoting the brittle of collagen fibers which in 
turn generates a deficiency in biomechanical strength. Critical 
stages of the fracture healing process, such as the inflammatory 
phase and vascularization, are altered by T2DM and this affects 
the dynamics of the mechanisms involved in successful bone 
repair. The impact of T2DM on bone fracture healing represents 
an important problem for patients suffering from diabetes, since 
bone fractures could lead to delayed healing, non-union, and 
post-surgery clinical complications such as risk of infection, 
amputation, and increased mortality. In addition, antidiabetic 
treatment has been associated with bone effects, in particular 
TZDs and SGLT2 inhibitors. Despite all the known negative 
consequences on bone repair and regeneration, the mechanisms 
involved in T2DM-induced skeletal impairment are not yet fully 
understood. Further investigation must be carried out to elucidate 
the pathophysiology of the diabetic bone and to develop success-
ful strategies to treat this growing medical and socioeconomical 
global complication.
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